Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Dean J. Bacich"'
Publikováno v:
Urologic Oncology: Seminars and Original Investigations. 32:272-279
Objective Despite a multitude of detection and treatment advances in the past 2 decades, prostate cancer remains the second leading cause of deaths due to cancer among men in the United States. Technological evolution and expanding knowledge of tumor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c41ac7cef130150eb2e08d24065eb174
https://doi.org/10.1016/j.urolonc.2013.09.003
https://doi.org/10.1016/j.urolonc.2013.09.003
Autor:
Dean J. Bacich, Warren D. W. Heston, Karolina J. Janczura, Tomasz Bzdega, Rafal T. Olszewski, Joseph H. Neale
Publikováno v:
European Journal of Pharmacology. 701:27-32
The peptide neurotransmitter N-acetylaspartylglutamate (NAAG) is inactivated by the extracellular enzyme glutamate carboxypeptidase II. Inhibitors of this enzyme reverse dizocilpine (MK-801)-induced impairment of short-term memory in the novel object
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::066159c4c83733297aa9d0bed72ee35a
https://doi.org/10.1016/j.ejphar.2012.11.027
https://doi.org/10.1016/j.ejphar.2012.11.027
Autor:
Dean J. Bacich, Denise S. O'Keefe, Kathryn M. Sobek, William R. Green, Allison A. Madigan, Jessica Cummings
Publikováno v:
Genes and immunity
Benign prostatic hyperplasia (BPH) is the most common urologic disease in men over age 50. Symptoms include acute urinary retention, urgency to urinate and nocturia. For patients with severe symptoms, surgical treatment is used to remove the affected
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d990039832a42957fa33e49276ac2ea7
https://doi.org/10.1038/gene.2012.40
https://doi.org/10.1038/gene.2012.40
Autor:
Christoph Maier, Laura J. Niedernhofer, Anil V. Parwani, Diana Sisca Harya, Veronica Yao, Andria Rasile Robinson, Dean J. Bacich, Derek J. Matoka, Jennifer L. Gregg
Publikováno v:
The Prostate. 72:1214-1222
Background The excision repair cross complementing (ERCC1) gene product plays a vital role in the nucleotide excision repair and DNA interstrand crosslink repair pathways, which protect the genome from mutations and chromosomal aberrations, respectiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ed804f2c071352599ccdccab07d01f3c
https://doi.org/10.1002/pros.22472
https://doi.org/10.1002/pros.22472
Autor:
Denise S. O'Keefe, Dean J. Bacich, Jeffrey J. Tomaszewski, Joel B. Mason, Joel B. Nelson, Anil V. Parwani, Rajiv Dhir, Jessica Cummings
Publikováno v:
The Prostate. 71:1287-1293
BACKGROUND A recent clinical trial revealed that folic acid supplementation is associated with an increased incidence of prostate cancer (Figueiredo et al., J Natl Cancer Inst 2009; 101(6): 432–435). As tumor cells in culture proliferate directly i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bedffb96a1a378f4f34a8c0d20bf29f0
https://doi.org/10.1002/pros.21346
https://doi.org/10.1002/pros.21346
Publikováno v:
The Prostate. 70:305-316
BACKGROUND. Prostate specific membrane antigen (PSMA) is a unique folate hydrolase that is significantly upregulated in prostate cancer. In a mouse model, PSMA is able to facilitate prostate carcinogenesis, however, little is known about the mechanis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4a10da28b51e0c85064192bee2adce38
https://doi.org/10.1002/pros.21065
https://doi.org/10.1002/pros.21065
Publikováno v:
Cancer Research. 68:9070-9077
Increased expression of PSMA, a differentiation antigen with folate hydrolase activity, is an independent marker of prostate cancer progression. Mice expressing moderate levels of human PSMA in their prostate develop PIN-like lesions by 9 months. The
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08484dc5b8f5c87218497102b509983f
https://doi.org/10.1158/0008-5472.can-08-2328
https://doi.org/10.1158/0008-5472.can-08-2328
Autor:
Uma R. Chandran, Uddhav P. Kelavkar, Denise S. O'Keefe, Justin Hutzley, N.S. Harya, Rajiv Dhir, Dean J. Bacich, Federico A. Monzon
Publikováno v:
Prostaglandins & Other Lipid Mediators. 82:185-197
Fifteen (15)-lipoxygenase type 1 (15-LO-1, ALOX15), a highly regulated, tissue- and cell-type-specific lipid-peroxidating enzyme has several functions ranging from physiological membrane remodeling, pathogenesis of atherosclerosis, inflammation and c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b091ffe42577df5e5d2adfc121d3fa0c
https://doi.org/10.1016/j.prostaglandins.2006.05.015
https://doi.org/10.1016/j.prostaglandins.2006.05.015
Autor:
Vandana Turaga, Polly D. Gregor, Jean Baptiste Latouche, Warren D. W. Heston, Michel Sadelain, Howard I. Scher, Jedd D. Wolchok, Alan N. Houghton, Dean J. Bacich
Publikováno v:
International Journal of Cancer. 116:415-421
Prostate-specific membrane antigen (PSMA) is a prototypical differentiation antigen expressed on normal and neoplastic prostate epithelial cells, and on the neovasculature of many solid tumors. Monoclonal antibodies specific for PSMA are in developme
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::980d7d35c1ed1f70ea3f18f9a2751e95
https://doi.org/10.1002/ijc.21014
https://doi.org/10.1002/ijc.21014
Autor:
Fariborz Mortazavi, Warren D. W. Heston, James P. Allison, Polly D. Gregor, Alan N. Houghton, Miguel-Angel Perales, Michel Sadelain, Dean J. Bacich, Heidi Buchinshky, Jean Baptiste Latouche, Howard I. Scher, José A. Guevara-Patiño, Jedd D. Wolchok, Cristina R. Ferrone
Publikováno v:
Vaccine. 22:1700-1708
Xenogeneic DNA vaccination can elicit tumor immunity through T cell and antibody-dependent effector mechanisms. Blockade of CTLA-4 engagement with B7 expressed on APCs has been shown to enhance T cell-dependent immunity. We investigated whether CTLA-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::220ad74e4dccc254e68a350ec355674c
https://doi.org/10.1016/j.vaccine.2003.10.048
https://doi.org/10.1016/j.vaccine.2003.10.048